Karyopharm Therapeutics Inc.KPTI

Karyopharm Therapeutics Inc. is a clinical-stage oncology outfit built around a single mechanistic promise: inhibit XPO1, the cell’s nuclear courier, and maybe-just maybe-turn the tide against hard-to-treat cancers. The company’s public story is all about first-in-class exportin-1 inhibition, with a pipeline of four programmes aimed at haematologic and solid tumour malignancies. Behind the science slide deck, though, sits a balance sheet that’s still learning to walk. The latest 10-Q for the quarter ending March 31 2026 shows revenue of $35.1 million, but that total is mostly licence fees rather than product sales, with $0.9 million from Menarini and $0.6 million from Antengene booked as royalty income for the three-month window. Net product revenue recognised in accounts receivable was $19.6 million at March 31 2026, down from $22.7 million at year-end 2025, a gentle reminder that the company’s commercial footprint is still early innings. (source: KPTI SEC EDGAR 10-Q, 2026-05-14, https://www.sec.gov/Archives/edgar/data/1503802/000119312526222827/kpti-20260331.htm)

The science is real enough. Karyopharm’s XPO1 platform is designed to block the protein that shuttles tumour-suppressor cargo out of the nucleus, restoring intracellular balance and, ideally, slowing cancer progression. The company’s clinical pipeline includes programmes like Selinexor, an oral XPO1 inhibitor already under investigation in myelofibrosis and other malignancies. Recent press releases trumpet a late-breaking oral presentation of Phase 3 SENTRY trial data for Selinexor plus Ruxolitinib in myelofibrosis at EHA 2026 and ASCO 2026, with simultaneous publication in the Journal of Clinical Oncology. The company also plans an investor call to walk analysts through the results once ASCO wraps. These are the moments biotech CEOs live for-data blasts that can lift a share price narrative even when the day-to-day revenue engine is idling. (source: Press Releases, https://investors.karyopharm.com/press-releases)

Now the numbers. For the quarter ended March 31 2026, Karyopharm reported revenue from contracts with customers, excluding assessed tax, of $35.1 million, a net loss attributable to parent of $22.4 million, and an operating loss of $26.8 million. Diluted earnings per share clocked in at $-1.24 on 24,715 weighted average shares outstanding. Cash and cash equivalents stood at $90.8 million, while total assets were $131.4 million against liabilities of $397.1 million, leaving shareholders’ equity at a negative $265.6 million. Operating cash burn was $22.7 million for the quarter, and R&D expense came in at $33.8 million. Inventory net was $3.6 million, down $439,000 from the prior period. Capital expenditure was zero for the 12 months ended December 31 2025, which tells you the company isn’t building factories-it’s outsourcing the heavy lifting. (source: KPTI SEC EDGAR 10-Q, 2026-05-14, https://www.sec.gov/Archives/edgar/data/1503802/000119312526222827/kpti-20260331.htm)

If you’re hunting for a chart route, the daily price data is available from your terminal of choice under the Karyopharm Therapeutics Inc. ticker (Nasdaq: KPTI). The file tracks a biotech name with a single-digit market capitalisation, thin float, and a clinical-stage story that rises and falls on every data readout, regulatory whisper, or institutional positioning shift. There are no guarantees, and the chart will happily remind you of that fact every time it gaps on a headline. (source: Nasdaq data feed, terminal route via SEC EDGAR index for CIK 1503802, https://www.sec.gov/edgar/browse/?CIK=1503802)

What changed this week? On May 28 2026, the company filed an 8-K disclosing a leadership transition, with the CEO’s departure noted alongside board updates. The board also authorised a new $150 million ATM equity programme in the same month, a classic biotech tool for keeping the lights on while the pipeline sorts itself out. Meantime, insiders continue to play the long game: directors’ RSUs vest only in 2027 and are contingent on change-of-control or departure, which is another way of saying the board is incentivised to find a buyer before the units hit the market. (source: KPTI 8-K, 2026-05-28, https://www.sec.gov/Archives/edgar/data/1503802/000150380226000027/kpti-20260521.htm)

What remains unproven? Karyopharm still hasn’t cracked the code on meaningful, recurring product revenue outside licence fees. The pipeline is promising but early, and Phase 3 data in myelofibrosis is critical path. Until the company can convert its science into durable sales or a clear path to profitability, the balance sheet will keep calling the tune, and the share count will keep ticking up via dilution. The next inflection point is the ASCO data drop and the investor call that follows. If the numbers impress, the stock can dance; if they disappoint, the cash burn clock keeps running. (source: KPTI SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1503802)